Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1956-1963

  Gangadhar, Tara C ^a   Cohen, Ezra E W ^a   Wu, Kehua ^a   Janisch, Linda ^a   Geary, David ^a   Kocherginsky, Masha ^a   House, Larry K ^a   Ramirez, Jackie ^a   Undevia, Samir D ^a   Maitland, Michael L ^a   Fleming, Gini F ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DRUG METABOLITE; RAPAMYCIN; SORAFENIB; SUNITINIB;

ADENOID CYSTIC CARCINOMA; ADRENAL CANCER; ADRENAL CORTEX TUMOR; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEASIBILITY STUDY; FEMALE; FIBROMATOSIS; GALLBLADDER CANCER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CANCER; KIDNEY INJURY; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUTH INFLAMMATION; NEUROBLASTOMA; NEUTROPENIA; OVARY CANCER; PAIN; PANCREAS CANCER; PAROTID GLAND CANCER; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SUPERIOR CAVA VEIN SYNDROME; TESTIS CANCER; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT DURATION; UROGENITAL TRACT CANCER; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BENZENESULFONATES; DRUG INTERACTIONS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; PYRIDINES; PYRROLES; SIROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953307456     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2061     Document Type: Article

References (43)

1. Failli A, Steffan R. American Home Products Corporation (New York, NY) assignee. Silyl ethers of rapamycin. Patent no. 5,120,842 1992, Jun 9.
2. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005;65:5325-36. (Pubitemid 40827345)
3. Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006;12:2613-21.
4. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 2008;26:4172-9.
5. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28:835-40.
6. Cohen EE. mTOR: the mammalian target of replication. J Clin Oncol 2008;26:348-9.
7. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007;82:381-8. (Pubitemid 47414349)
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
11. Casali PG, Garrett CR, Blackstein ME, Shah M, Verweij J, McArthur G, et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006;24Suppl:abstr 9513.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 2007;846:1-7. (Pubitemid 46149480)
14. Beal S, Sheiner L. NONMEM Users Guide. San Francisco, CA: University of California, San Francisco; 1989.
15. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61. (Pubitemid 40826133)
16. Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer. Available from: http://clinicaltrials. gov/ct2/show/NCT00392821?term=sorafenib+everolimus&rank=4 [cited 2010 Jun 25].
17. Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00828594?term=sorafenib± everolimus&rank=3 [cited 2010 Jun 25].
18. Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01005199?term=sorafenib+everolimus& rank=9 [cited 2010 Jun 25].
19. Sorafenib in Combination WithRAD001 in Patients With Advanced Neuroendocrine Tumors. Available from:http://clinicaltrials.gov/ct2/show/ NCT00942682?term=sorafenib±everolimus&rank=7 [cited 2010 Jun 25].
20. Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01141309?term=sorafenib± everolimus&rank=2 [cited 2010 Jun 25].
21. Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma. Available from: http://clinicaltrials.gov/ct2/ show/NCT00474929?term=sorafenib±everolimus&rank =8 [cited 2010 Jun 25].
22. Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride. Available from: http://clinicaltrials.gov/ct2/show/ NCT00981162?term=sorafenib±everolimus&rank=5 [cited 2010 Jun 25].
23. Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib. Available from: http://clinicaltrials.gov/ct2/show/NCT00474786?term=sorafenib±and± temsirolimus&rank=10 [cited 2010 Jun 25].
24. Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer. Available from: http://clinicaltrials.gov/ ct2/show/NCT01025453?term=sorafenib+and+temsirolimus&rank=1 [cited 2010 Jun 25].
25. Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01008917?term= sorafenib+and+temsirolimus&rank=6 [cited 2010 Jun 25].
26. Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma. Available from: http://clinicaltrials.gov/ ct2/show/NCT00349206?term=sorafenib±and±temsirolimus&rank=4 [cited 2010 Jun 25].
27. Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00-329719? term=sorafenib±and±temsirolimus&rank=2 [cited 2010 Jun 25].
28. Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal CellCarcinoma (RECORD-3). Available from: http://clinicaltrials.gov/ct2/show/ NCT00903175?term=sunitinib±everolimus&rank=2 [cited 2010 Jun 25].
29. Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC). Available from: http://clinicaltrials.gov/ct2/show/NCT01122615?term= sunitinib+and+temsirolimus&rank=1 [cited 2010 Jun 25].
30. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92.
31. van Erp NP, Baker SD, Zandvliet AS, Ploefer BA, den Hollander M, Chen Z, et al. Marginal increase of sunitinib exposure by grapefruit juice Cancer Chemother Pharmacol 2011;67:695-703
32. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009;279:74-83.
33. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006;58:374-83. (Pubitemid 43800742)
34. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062-9.
35. Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, et al. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol 2007;60:179-88. (Pubitemid 46742532)
36. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009;37:359-65.
37. Kim K, Davies M, Papadopoulos N, Bedikian AY, Hwu W, Woodard K, et al. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J Clin Oncol 2009;27:abstr 9026.
38. Cen P, Daleiden A, Doshi D, Amato R. A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:e16056.
39. Kroog GS, Feldman DR, Kondagunta GV, Ginsberg MS, Fischer PM, Trinos MJ, et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:abstr 5037.
40. Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol 2009;27 Suppl;abstr 2006.
41. Fischer P, Patel P, Carducci MA, McDermott DF, Hudes GR, Lubiniecki GM, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol 2008;26:abstr 16020.
42. Hamberg P, Ratain MJ, Lesaffre E, Verweij J. Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 2010;46:2870-8.
43. Ratain MJ, Napoli KL, Knightley MK, Jiang X, Fleming GF, Gajewski TF, et al. A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies. J Clin Oncol 2007;25: Suppl:abstr 3510.